1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
GlobeImmune, Inc.

GlobeImmune, Inc.

GBIM
GlobeImmune, Inc.US flagOther OTC
0.00
USD
- -
- -
575.00Market Cap
2010 Y
2011 Y
2012 Y
2013 Y
2014 Y
2015 Y
TTM
Revenue per Share
42.54
53.42
153.12
235.49
2.05
1.12
1.08
Basic EPS, GAAP
-265.17
-261.88
-147.65
-35.64
-8.04
-0.48
-0.36
Free Cash Flow per Basic Share
-210.91
-53.73
-137.8
40.99
-3.55
-1.25
-1.03
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-1,649.37
-1,907.48
-2,051.04
-2,084.48
-76.41
-39.2
-39.35
Tangible Book Value per Share
-1,649.37
-1,907.48
-2,051.04
-2,084.48
1.92
0.52
0.37
Basic Weighted Avg Shares
- -
- -
- -
- -
3
6
6
Sales/Revenue/Turnover
4
5
15
23
6
6
6
Operating Margin (%)
-387.31
-246.55
-27.09
34.14
-97.53
-42.85
-33.3
Depreciation Expense
1
1
1
1
- -
- -
- -
Net Income, GAAP
-15
-14
-2
9
-16
-3
-2
Effective Tax Rate (%)
- -
- -
- -
1.21
- -
- -
- -
Profit Margin (%)
-363.63
-268.7
-13.76
42.08
-272.54
-42.85
-33.3
Working Capital
14
2
-5
- -
13
7
5
LT Debt
- -
- -
- -
- -
- -
- -
- -
Total Equity
-158
-182
-196
-199
6
3
2
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
-4.8
- -
- -
1.67
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Sep'15
Dec'15
Mar'16
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
6
6
6
Market Capitalization
15
22
12

Working Capital

FRC

•

in mil. unless spec.
Sep'15
Dec'15
Mar'16
Total Current Assets
13
11
9
Cash, Cash Equivalents & STI
11
10
9
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
4
4
4
Payables & Accruals
1
1
1
ST Debt
- -
- -
- -
Deferred Revenue
3
3
3

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-24.93%
-46.67%
Free Cash Flow
- -
-88.5%
-30.74%
Net Income, GAAP
- -
-203.49%
-82.98%
Sales/Revenue/Turnover
- -
40.15%
8.24%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2014
1
2
1
2
6
2015
1
1
3
1
6
2016
1
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2014
-1.07
-1.66
-1.18
- -
-8.04
2015
-0.27
-0.23
0.16
- -
-0.48
2016
-0.15
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2014
- -
- -
- -
- -
- -
2015
- -
- -
- -
- -
- -
2016
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Donald Bellgrau
Full Time Employees
2
Sector
Healthcare
Industry
Biotechnology
Address
1450 Infinite Drive Louisville CO United States of America 80027
IPO Date
Jul 2, 2014
CIK
0001245104
Website
globeimmune.com
Similar Companies
DMS Imaging S.A. (DMSIM.BR)
Pharma Mar, S.A. (0RC6.L)
Q32 Bio Inc. (0T6G.L)
EPIRUS Biopharmaceuticals, Inc. (EPRSQ)
Actinium Pharmaceuticals, Inc. (ATNM)
BiOptic Inc. (6850.TWO)
Business
GlobeImmune, Inc. (GBIM) is a clinical-stage biopharmaceutical company headquartered in Louisville, Colorado, and founded in 1995 that develops therapeutic vaccines for cancer and infectious diseases based on its proprietary Tarmogen platform; Tarmogens consist of genetically modified yeast expressing disease-associated antigens to activate T cells targeting infected or malignant cells. Core products include GI-4000 targeting mutated Ras proteins in pancreas cancer, non-small cell lung cancer, colorectal cancer and other Ras-mutated solid tumors; GI-6207 against CEA in solid tumors; GI-6301 targeting Brachyury protein in various cancers; GS-4774 (formerly GI-4774) for chronic hepatitis B virus infection; and earlier candidates such as GI-5005 for hepatitis C and GI-2010 for HIV, with preclinical programs including GI-7000 for melanoma and GI-19000 for tuberculosis. The company operates primarily in the United States with partnerships including Celgene Corporation since 2009 for oncology Tarmogens and the National Cancer Institute for cancer vaccines, though its Gilead Sciences collaboration for hepatitis B ended in November 2016 following clinical failure; in March 2017, NantCell, Inc. acquired a controlling interest and exclusive rights to GI-6207, GI-6301 and preclinical GI-6100, restarting manufacturing at its Louisville facility to supply trials, while GlobeImmune operates as a subsidiary of ImmunityBio, Inc. with no marketed products as of recent updates.